Products - Thyroid cancer | Topic | NICE

Showing 4 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Pralsetinib for thyroid cancer [ID4018]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC